Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 14:S0302-2838(25)00436-1.
doi: 10.1016/j.eururo.2025.07.019. Online ahead of print.

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

Nicolas Demogeot  1 , Paul Sargos  2 , Julia Salleron  3 , Stéphane Guérif  4 , Renaud de Crevoisier  5 , Gilles Calais  6 , Jean-Michel Hannoun-Levi  7 , Grégoire Bouché  8 , Christophe Hennequin  9 , Jacques Cretin  10 , Nassim Sahki  3 , Vincent Marchesi  11 , Yazid Belkacemi  12 , Jonathan Khalifa  13 , David Azria  14 , Nicolas Bauer  15 , Pascal Pommier  16 , Jean-Marc Simon  17 , Catherine Léger  18 , Véronique Beckendorf  19 , Bernard Dubray  20 , Stéphane Supiot  21 ; Groupe d’Etude des Tumeurs Uro-Génitales (GETUG)
Affiliations
Free article

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

Nicolas Demogeot et al. Eur Urol. .
Free article

Abstract

Background and objective: Few studies have compared short-term androgen deprivation (STADT) combined with high-dose radiotherapy (STADT-RT) versus high-dose radiotherapy (RT) alone in localized prostate cancer.

Methods: The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT. Disease-free survival (DFS) was the primary endpoint. Secondary endpoints were overall survival (OS), biochemical failure (BF), metastasis failure (MF), toxicity, and quality of life.

Key findings and limitations: Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer. At median follow-up among surviving patients of 84 mo (interquartile range 62-99 mo), the 5-yr DFS rate was 76% in RT arm versus 84% in STADT-RT arm (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.43-0.94]). ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29). There were no significant differences for RT versus STADT-RT in the incidence rates for grade ≥2 toxicity in terms of acute gastrointestinal (GI) toxicity (26%, 95% CI 20-32 vs 26%, 95% CI 20-33), acute genitourinary (GU) toxicity (39%, 95% CI 32-46% vs 42%, 95% CI 35-50%), late GI toxicity (21%, 95% CI 16-28% vs 23%, 95% CI 18-30%), or late GU toxicity (30%, 95% CI 24-38% vs 27%, 95% CI 21-34%).

Conclusions and clinical implications: STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.

Keywords: Androgen deprivation Therapy; Prostate cancer; Radiotherapy; Randomized trial.

PubMed Disclaimer

LinkOut - more resources